Tesamorelin Results Timeline

What does the tesamorelin results timeline actually show?

The published timeline is a set of group-mean measurements at fixed study visits, and the headline endpoint is a roughly 15 percent drop in visceral fat by week 26 (Falutz et al., 2007).

Tesamorelin was studied as a growth hormone releasing factor analog. In the trial reported by Falutz et al. (2007) in the New England Journal of Medicine, the primary endpoint was change in visceral adipose tissue, the deep abdominal fat around the organs, measured by CT scan. The study compared tesamorelin against placebo over 26 weeks in adults with excess visceral fat.

The reported result: the tesamorelin group showed a mean VAT reduction of about 15.2 percent, while the placebo group showed a mean VAT increase of about 5.0 percent (Falutz et al., 2007). That gap between the two groups is the core of what "results" means in this compound's evidence base.

Read those numbers as what happened across a group. They are not a schedule of what will happen to any single person.

When were measurements taken in the trial?

Change was recorded at set clinical visits across the 26 week study, not continuously.

Trials measure at scheduled points rather than day by day. In the tesamorelin visceral fat program, imaging and lab endpoints were captured at fixed visits across the 26 week period, with the primary VAT endpoint reported at week 26 (Falutz et al., 2007). This matters for anyone reading a "timeline": the published data tells you where the measurement points were, not that fat loss is linear or that any given week produces a set amount of change.

Because the endpoint is a group average at a study visit, individual participants varied around that mean. A group mean of about 15.2 percent VAT reduction includes people above and below that figure (Falutz et al., 2007).

Reported tesamorelin trial figures

The table shows the group-mean values as reported. These are observed study results, not target values and not a dosing recommendation.

Note on dose: in the trial, participants received tesamorelin as a daily subcutaneous injection under study conditions (Falutz et al., 2007). We report that this is how the study was run. We do not tell you what to take, how much, or how to inject. Any personal protocol is a clinician's decision.

How does tesamorelin compare with other growth hormone secretagogues?

Tesamorelin is the one in this class with a randomized trial reporting a specific visceral fat endpoint, while related peptides have different or narrower evidence.

Tesamorelin raises growth hormone by acting as a releasing factor analog (Falutz et al., 2007). Other compounds in the broad growth hormone axis work differently and have separate data:

• CJC-1295 was reported to produce sustained increases in GH and IGF-1 in a controlled study (Teichman et al., 2006). That is a hormone-level finding, not a visceral fat endpoint.
• Ipamorelin was described as a selective GH secretagogue in preclinical work (Raun et al., 1998).
• MK-677, an oral secretagogue, raised GH but was also reported to raise fasting glucose and lower insulin sensitivity (Nass et al., 2008).

The point for a results timeline: only tesamorelin's pivotal trial reports the roughly 15 percent VAT figure at 26 weeks (Falutz et al., 2007). Do not transfer that number onto other peptides.

What happens after the studied window?

Published data covers the trial period; what happens after stopping is not well described in a single clean long-term dataset here.

The Falutz et al. (2007) trial reports change through 26 weeks. For a broader pattern across metabolic therapies, withdrawal of an active agent has been associated with regression of benefit in other compound classes: for example, weight regain after stopping was reported for GLP-1 therapies (Wilding et al., 2022; Aronne et al., 2024). That is a different drug class and is offered only as context on why sustained effect and continued measurement matter, not as a tesamorelin finding. For tesamorelin specifically, treat the 26 week trial as the boundary of the strong reported timeline.